Experience With Pre-procedural Hemostatic Medications versus Platelet Transfusion in Patients With Platelet Storage Pool Deficiency.

Autor:	Lundy KA; Department of Pharmacy, The Ohio State University Wexner Medical Center, Columbus, OH, USA., Rabatin A; Department of Pharmacy, The Ohio State University Wexner Medical Center, Columbus, OH, USA., Davidson ER; Department of Pharmacy, The Ohio State University Wexner Medical Center, Columbus, OH, USA., Li J; The Ohio State University College of Pharmacy, Columbus, OH, USA., Snider MJ; Department of Pharmacy, The Ohio State University Wexner Medical Center, Columbus, OH, USA., Kraut EH; Division of Hematology & Oncology, The James Cancer Hospital and Solove Research Institute, Columbus, OH, USA.
Jazyk:	angličtina
Zdroj:	Journal of pharmacy practice [J Pharm Pract] 2023 Dec; Vol. 36 (6), pp. 1412-1418. Date of Electronic Publication: 2022 Aug 17.
DOI:	10.1177/08971900221119167
Abstrakt:	BackgroundStorage pool deficiency (SPD) is a rare bleeding disorder characterized by reduction in the number of delta granules within platelets, interfering with hemostasis. Current literature lacks well-designed studies from which to draw concrete conclusions regarding pre-procedural management of bleeding complications. Objective: The purpose of this study is to describe bleeding and safety outcomes of SPD patients receiving either pre-procedural platelet transfusions or platelet-sparing regimens. Methods: An exploratory retrospective cohort study was conducted among SPD patients, comparing major bleeding events between those who received platelet transfusion and those who received desmopressin, tranexamic acid, and/or aminocaproic acid within 24 hours prior to procedure. Results: Rates of major bleeding were not found to be higher among patients who received a platelet-sparing regimen [platelet-sparing: 2/25 (8%); platelet transfusion: 2/29 (6.9%); P = .99]. Incidence of non-major bleeding was higher in the platelet transfusion group, but this was not statistically significant [platelet-sparing: 0/25 (0%); platelet transfusion: 3/29 (10.3%); P = .24]. Treatment-related adverse effects were observed following 8 of 54 procedures (14.8%). Conclusion: Use of a platelet-sparing regimen was not associated with a significantly higher incidence of major or non-major bleeding events. Future prospective trials are recommended to compare outcomes between therapies. Competing Interests: Declaration of conflicting interestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu